These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33753750)

  • 1. The therapeutic implications of the genomic analysis of malignant pleural mesothelioma.
    Zauderer MG
    Nat Commun; 2021 Mar; 12(1):1819. PubMed ID: 33753750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
    Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
    Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic analysis in short- and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy.
    Torricelli F; Saxena A; Nuamah R; Neat M; Harling L; Ng W; Spicer J; Ciarrocchi A; Bille A
    Eur J Cancer; 2020 Jun; 132():104-111. PubMed ID: 32339978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
    Disselhorst MJ; Quispel-Janssen J; Lalezari F; Monkhorst K; de Vries JF; van der Noort V; Harms E; Burgers S; Baas P
    Lancet Respir Med; 2019 Mar; 7(3):260-270. PubMed ID: 30660511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A patient with malignant pleural mesothelioma carrying BRAF V600E mutation responding to vemurafenib.
    Chen Y; Chen B; Zhu X; Zhong J
    Lung Cancer; 2018 Feb; 116():96-98. PubMed ID: 29146159
    [No Abstract]   [Full Text] [Related]  

  • 6. NICE guidance on nivolumab plus ipilimumab for untreated, unresectable malignant pleural mesothelioma.
    Adler AI; Slayen S; Stegenga H; Guo Y; Diaz R; Welton NJ; Westwood N; Doull I; Crawley C
    Lancet Respir Med; 2022 Oct; 10(10):e92-e93. PubMed ID: 35988573
    [No Abstract]   [Full Text] [Related]  

  • 7. A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.
    Fujimoto N; Aoe K; Kozuki T; Oze I; Kato K; Kishimoto T; Hotta K
    Clin Lung Cancer; 2018 Sep; 19(5):e705-e707. PubMed ID: 29853412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma.
    Nakajima EC; Vellanki PJ; Larkins E; Chatterjee S; Mishra-Kalyani PS; Bi Y; Qosa H; Liu J; Zhao H; Biable M; Hotaki LT; Shen YL; Pazdur R; Beaver JA; Singh H; Donoghue M
    Clin Cancer Res; 2022 Feb; 28(3):446-451. PubMed ID: 34462287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new standard for malignant pleural mesothelioma.
    Zauderer MG
    Lancet; 2016 Apr; 387(10026):1352-1354. PubMed ID: 26719231
    [No Abstract]   [Full Text] [Related]  

  • 10. Proton-coupled folate transporter as a biomarker of outcome to treatment for pleural mesothelioma.
    Petri GL; Cascioferro S; Parrino B; Peters GJ; Diana P; Giovannetti E
    Pharmacogenomics; 2018 Jul; 19(10):811-814. PubMed ID: 29916298
    [No Abstract]   [Full Text] [Related]  

  • 11. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
    Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE
    Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New MAA: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma].
    Laune Q; Brosseau S
    Bull Cancer; 2022 Jan; 109(1):4-6. PubMed ID: 34654542
    [No Abstract]   [Full Text] [Related]  

  • 13. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy.
    Hassan R; Morrow B; Thomas A; Walsh T; Lee MK; Gulsuner S; Gadiraju M; Panou V; Gao S; Mian I; Khan J; Raffeld M; Patel S; Xi L; Wei JS; Hesdorffer M; Zhang J; Calzone K; Desai A; Padiernos E; Alewine C; Schrump DS; Steinberg SM; Kindler HL; King MC; Churpek JE
    Proc Natl Acad Sci U S A; 2019 Apr; 116(18):9008-9013. PubMed ID: 30975761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesothelioma: closer to the target?
    Pass HI
    Lancet Oncol; 2013 May; 14(6):448-9. PubMed ID: 23583605
    [No Abstract]   [Full Text] [Related]  

  • 15. Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma.
    Mairinger FD; Vollbrecht C; Flom E; Christoph DC; Schmid KW; Kollmeier J; Popper HH; Mairinger T; Walter RFH
    Oncotarget; 2017 Jun; 8(23):37502-37510. PubMed ID: 28415584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
    Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
    Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic Modifier UHRF1 May Be a Potential Target in Malignant Pleural Mesothelioma.
    Baird AM; Finn SP; Gray SG; Sheils O
    J Thorac Oncol; 2021 Jan; 16(1):14-16. PubMed ID: 33384056
    [No Abstract]   [Full Text] [Related]  

  • 18. High RRM1 Expression Is Associated with Adverse Outcome in Patients with Cisplatin/Vinorelbine-treated Malignant Pleural Mesothelioma.
    Zimling ZG; Santoni-Rugiu E; Bech C; Sørensen JB
    Anticancer Res; 2015 Dec; 35(12):6731-8. PubMed ID: 26637889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?
    Bronte G; Incorvaia L; Rizzo S; Passiglia F; Galvano A; Rizzo F; Rolfo C; Fanale D; Listì A; Natoli C; Bazan V; Russo A
    Crit Rev Oncol Hematol; 2016 Nov; 107():20-32. PubMed ID: 27823648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features.
    Marqués M; Tranchant R; Risa-Ebrí B; Suárez-Solís ML; Fernández LC; Carrillo-de-Santa-Pau E; Del Pozo N; Martínez de Villarreal J; Meiller C; Allory Y; Blum Y; Pirker C; Hegedus B; Barry ST; Carnero A; Berger W; Jean D; Real FX
    Cancer Res; 2020 Feb; 80(4):843-856. PubMed ID: 31911549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.